Ozempic Maker Novo Nordisk Sees 50% Share Price Plummet Due to Competition and Copycats
Novo Nordisk’s share price has plummeted more than 50% this year, pushing the Danish drugmaker out of Europe’s top ten most valuable companies. The company behind the popular diabetes drug Ozempic is struggling due to increased competition from Eli Lilly’s Mounjaro and cheap copycat versions. In May, Novo Nordisk announced it would replace its chief … Read more